IP Library › Granted Patent US 11,254,640
Granted Patent B2
US 11,254,640 · App. 17/345,471 · Granted Feb 22, 2022

N-substituted indoles and other heterocycles for treating brain disorders

Inventors: David E. Olson (Davis, CA); Lee Dunlap (Davis, CA); Florence Wagner (Davis, CA)
Assignee: The Regents of the University of California
C07D209/08A61K31/4045A61P25/24C07D209/14C07D401/06C07D403/06C07D491/044
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,254,640
App. No.
17/345,471
Granted
Feb 22, 2022
Kind
B2
Abstract

The present invention provides N-substituted indoles and other heterocycles and methods of using the compounds for treating brain disorders.

Claims (45)

1. A compound selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , which is

or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1 , which is

or a pharmaceutically acceptable salt thereof.

4. The compound of claim 1 , which is

or a pharmaceutically acceptable salt thereof.

5. The compound of claim 1 , which is

or a pharmaceutically acceptable salt thereof.

6. The compound of claim 1 , which is

or a pharmaceutically acceptable salt thereof.

7. The compound of claim 1 , which is

or a pharmaceutically acceptable salt thereof.

8. The compound of claim 1 , which is

or a pharmaceutically acceptable salt thereof.

9. The compound of claim 1 , which is

or a pharmaceutically acceptable salt thereof.

10. The compound of claim 1 , which is

or a pharmaceutically acceptable salt thereof.

11. The compound of claim 1 , which is

or a pharmaceutically acceptable salt thereof.

12. A method for treating a brain disorder, comprising administering to a subject in need thereof, a therapeutically effective amount of a compound according to claim 1 , or a pharmaceutically acceptable salt thereof.

13. The method of claim 12 , wherein the brain disorder is a psychological disorder, depression, addiction, anxiety, or post-traumatic stress disorder.

14. The method of claim 13 , wherein the brain disorder is depression or addiction.

15. The method of claim 12 , wherein the brain disorder is treatment resistant depression, suicidal ideation, major depressive disorder, bipolar disorder, schizophrenia, or substance use disorder.

16. A pharmaceutical composition, comprising a therapeutically effective amount of a compound selected from claim 1 , or a pharmaceutically acceptable salt thereof.

17. The pharmaceutical composition of claim 16 , selected from the group consisting of:

or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

18. The pharmaceutical composition of claim 17 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

19. The pharmaceutical composition of claim 17 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

20. The pharmaceutical composition of claim 17 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

21. The pharmaceutical composition of claim 17 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

22. The pharmaceutical composition of claim 17 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

23. The pharmaceutical composition of claim 17 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

24. The pharmaceutical composition of claim 17 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

25. The pharmaceutical composition of claim 17 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 1, 2021
From: OLSON, DAVID E; DUNLAP, LEE; WAGNER, FLORENCE F.
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA CORPORATION
Reel/Frame 057669/0724 →
Continuity (4)
Continuation PCTUS2020019856 · Feb 26, 2020
Provisional Application 62958220 · Jan 7, 2020
Provisional Application 62811206 · Feb 27, 2019
Related Publication 20210332012A1 · Oct 28, 2021
Cited By (3)
US 12,295,959 US 12,325,710 US 12,637,464